Info
- Utilizzare la checkbox di selezione a fianco di ciascun documento per attivare le funzionalità di stampa, invio email, download nei formati disponibili del (i) record.
AIDS [[electronic resource]]
| AIDS [[electronic resource]] |
| Autore | Aggleton Peter |
| Pubbl/distr/stampa | Hoboken, : Taylor and Francis, 1995 |
| Descrizione fisica | 1 online resource (237 p.) |
| Disciplina | 362.1/969792 |
| Altri autori (Persone) |
DaviesPeter (Peter M.)
HartGraham <1957-> |
| Collana | Social Aspects of AIDS |
| Soggetto topico |
AIDS (Disease)
AIDS (Disease) - Social aspects HIV Infections Sociology Slow Virus Diseases Probability Acquired Immunodeficiency Syndrome Risk Social Environment Virus Diseases Statistics as Topic Lentivirus Infections Sexually Transmitted Diseases, Viral Mathematical Concepts Social Sciences Immunologic Deficiency Syndromes Phenomena and Processes Sexually Transmitted Diseases Anthropology, Education, Sociology and Social Phenomena Diseases Health Care Evaluation Mechanisms Retroviridae Infections Immune System Diseases Epidemiologic Methods Quality of Health Care Investigative Techniques Public Health RNA Virus Infections Environment and Public Health Analytical, Diagnostic and Therapeutic Techniques and Equipment Health Care Quality, Access, and Evaluation Health Care Communicable Diseases Health & Biological Sciences |
| Soggetto genere / forma | Electronic books. |
| ISBN |
9982-19-047-4
0-203-36253-5 1-135-74692-3 1-280-02179-9 9786610021796 |
| Formato | Materiale a stampa  |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Book Cover; Title; Contents; Preface; Reputedly Effective Risk Reduction Strategies and Gay Men; HIV-Related Discrimination in Medical Teaching Texts; Travel, Sexual Behaviour and Gay Men; Sexual Behaviour in Gay Men: Towards a Sociology of Risk; Framing Difference: Sexuality, AIDS and Organization; Towards Effective Inter vention: Evaluating HIV Prevention and Sexual Health Education Interventions; Communities, Governments and AIDS: Making Partnerships Work; Socially Apart Youth: Priorities for HIV Prevention
Theorizing and Researching 'Risk': Notes on the Social Relations of Risk in Heroin Users' LifestylesSex, Love and Seropositivity: Balancing the Risks; One of Us, One of Them, or One of Those? The Construction of Identity and Sexuality in Relation to HIV/AIDS; Sexuality, Identity and Community; Reflections on the MESMAC Project; Discourses of Power and Empowerment in the Fight Against HIV/AIDS in Africa; Notes on Contributors; Index |
| Record Nr. | UNISA-996207278803316 |
Aggleton Peter
|
||
| Hoboken, : Taylor and Francis, 1995 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. di Salerno | ||
| ||
AIDS : the making of a chronic disease
| AIDS : the making of a chronic disease |
| Pubbl/distr/stampa | [Place of publication not identified], : University of California Press, 1992 |
| Disciplina | 614.5/993 |
| Soggetto topico |
AIDS (Disease) - History
Financial Support Health Personnel Homosexuality Mass Media Social Control, Formal State Government Substance-Related Disorders Blood Donors Confidentiality Delivery of Health Care Government Acquired Immunodeficiency Syndrome Blood Transfusion Education History Legislation Local Government Health Policy Hemophilia A Human Experimentation Jurisprudence Public Health Minority Groups Federal Government Government Regulation HIV Seropositivity Public Policy International Cooperation Developing Countries Chronic Disease Women Politics AIDS Serodiagnosis Ethics, Medical Internationality Pharmaceutical Preparations Employment Poverty Prejudice Epidemiology Publication Formats Patient Care Management Tissue Donors Environment and Public Health Economics Health Care Facilities, Manpower, and Services Medicine Patient Rights Forensic Psychiatry Diseases Health Sociology Disease Attributes Persons HIV Infections Blood Coagulation Disorders, Inherited Social Control Policies Health Care Quality, Access, and Evaluation Investigative Techniques Biological Therapy Serologic Tests Organizations Social Sciences Sexuality Coagulation Protein Disorders Anthropology, Education, Sociology and Social Phenomena Humanities Psychology, Social Social Problems Hemorrhagic Disorders Socioeconomic Factors Health Care Economics and Organizations Chemicals and Drugs Ethics, Clinical Research Slow Virus Diseases Occupational Groups Biomedical Research Communications Media Mental Disorders Health Care Genetic Diseases, Inborn Policy Behavior and Behavior Mechanisms Immunologic Deficiency Syndromes Human Rights Immunologic Tests Science Sexually Transmitted Diseases, Viral Population Characteristics Therapeutics Virus Diseases Psychiatry and Psychology Publication Characteristics Sexual Behavior Psychiatry Reproductive Physiological Phenomena Health Services Administration Named Groups Information Science Analytical, Diagnostic and Therapeutic Techniques and Equipment Ethics, Professional Blood Coagulation Disorders Pathologic Processes Lentivirus Infections Hematologic Diseases Health Occupations Congenital, Hereditary, and Neonatal Diseases and Abnormalities Ethics Immunologic Techniques Sexually Transmitted Diseases Immune System Diseases Laboratory Techniques and Procedures Behavior Pathological Conditions, Signs and Symptoms Retroviridae Infections Hemic and Lymphatic Diseases Reproductive and Urinary Physiological Phenomena Natural Science Disciplines Disciplines and Occupations Behavioral Sciences RNA Virus Infections Diagnosis Phenomena and Processes Behavioral Disciplines and Activities Communicable Diseases Health & Biological Sciences |
| ISBN | 0-520-07569-2 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Altri titoli varianti | AIDS |
| Record Nr. | UNINA-9910495891403321 |
| [Place of publication not identified], : University of California Press, 1992 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Alcohol consumption and cancer risk : understanding possible causal mechanisms for breast and colorectal cancers
| Alcohol consumption and cancer risk : understanding possible causal mechanisms for breast and colorectal cancers |
| Pubbl/distr/stampa | [Place of publication not identified], : Agency for Healthcare Research and Quality, 2010 |
| Descrizione fisica | 1 online resource (ix, 81 p.) |
| Collana |
AHRQ Publication
Evidence Report/Technology Assessment |
| Soggetto topico |
Risk
Breast Diseases Drinking Behavior Colonic Diseases Intestinal Neoplasms Causality Neoplasms by Site Rectal Diseases Gastrointestinal Neoplasms Neoplasms Probability Intestinal Diseases Behavior Epidemiologic Factors Skin Diseases Diseases Behavior and Behavior Mechanisms Gastrointestinal Diseases Statistics as Topic Skin and Connective Tissue Diseases Digestive System Neoplasms Quality of Health Care Public Health Digestive System Diseases Environment and Public Health Epidemiologic Methods Health Care Quality, Access, and Evaluation Health Care Evaluation Mechanisms Health Care Investigative Techniques Diagnostic Techniques and Procedures Breast Neoplasms Risk Factors Colorectal Neoplasms Alcohol Drinking Medicine Health & Biological Sciences Oncology |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Record Nr. | UNINA-9910703239203321 |
| [Place of publication not identified], : Agency for Healthcare Research and Quality, 2010 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
| Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance |
| Autore | Organization World Health |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2014 |
| Descrizione fisica | 1 online resource (254 p.) |
| Disciplina | 616 |
| Soggetto topico |
Drug resistance -- Periodicals
Drug resistance in microorganisms Drug resistance Anti-infective agents - Classification Drug resistance in microorganisms - Effect of drugs on Risk management Risk Risk Management Information Science Drug Resistance Microbiological Phenomena Epidemiologic Measurements Therapeutic Uses Probability Pharmacologic Actions Pharmacological Phenomena Public Health Organization and Administration Statistics as Topic Health Services Administration Environment and Public Health Chemical Actions and Uses Physiological Phenomena Health Care Evaluation Mechanisms Health Care Epidemiologic Methods Drug Therapy Quality of Health Care Investigative Techniques Diagnostic Techniques and Procedures Health Care Quality, Access, and Evaluation Anti-Infective Agents Classification Risk Assessment Drug Resistance, Microbial Biology Health & Biological Sciences Microbiology & Immunology |
| Soggetto genere / forma |
Electronic books.
Publication Formats Technical Report |
| ISBN | 92-4-069266-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment 4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses 4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine 5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material |
| Record Nr. | UNINA-9910511992203321 |
|
Organization World Health
|
||
| Geneva, : World Health Organization, 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
| Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance |
| Autore | Organization World Health |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2014 |
| Descrizione fisica | 1 online resource (254 p.) |
| Disciplina | 616 |
| Soggetto topico |
Drug resistance -- Periodicals
Drug resistance in microorganisms Drug resistance Anti-infective agents - Classification Drug resistance in microorganisms - Effect of drugs on Risk management Risk Risk Management Information Science Drug Resistance Microbiological Phenomena Epidemiologic Measurements Therapeutic Uses Probability Pharmacologic Actions Pharmacological Phenomena Public Health Organization and Administration Statistics as Topic Health Services Administration Environment and Public Health Chemical Actions and Uses Physiological Phenomena Health Care Evaluation Mechanisms Health Care Epidemiologic Methods Drug Therapy Quality of Health Care Investigative Techniques Diagnostic Techniques and Procedures Health Care Quality, Access, and Evaluation Anti-Infective Agents Classification Risk Assessment Drug Resistance, Microbial Biology Health & Biological Sciences Microbiology & Immunology |
| Soggetto genere / forma |
Publication Formats
Technical Report |
| ISBN | 92-4-069266-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment 4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses 4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine 5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material |
| Record Nr. | UNINA-9910786624203321 |
|
Organization World Health
|
||
| Geneva, : World Health Organization, 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance
| Antimicrobial Resistance. Global Report on Surveillance [[electronic resource] ] : Global Report on Surveillance |
| Autore | Organization World Health |
| Pubbl/distr/stampa | Geneva, : World Health Organization, 2014 |
| Descrizione fisica | 1 online resource (254 p.) |
| Disciplina | 616 |
| Soggetto topico |
Drug resistance -- Periodicals
Drug resistance in microorganisms Drug resistance Anti-infective agents - Classification Drug resistance in microorganisms - Effect of drugs on Risk management Risk Risk Management Information Science Drug Resistance Microbiological Phenomena Epidemiologic Measurements Therapeutic Uses Probability Pharmacologic Actions Pharmacological Phenomena Public Health Organization and Administration Statistics as Topic Health Services Administration Environment and Public Health Chemical Actions and Uses Physiological Phenomena Health Care Evaluation Mechanisms Health Care Epidemiologic Methods Drug Therapy Quality of Health Care Investigative Techniques Diagnostic Techniques and Procedures Health Care Quality, Access, and Evaluation Anti-Infective Agents Classification Risk Assessment Drug Resistance, Microbial Biology Health & Biological Sciences Microbiology & Immunology |
| Soggetto genere / forma |
Publication Formats
Technical Report |
| ISBN | 92-4-069266-5 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Cover; Contents; Foreword; Summary; Acknowledgements; Abbreviations; Introduction; SECTION 01 Resistance to antibacterial drugs; 1.1 Background; 1.1.1 Limitations; 1.2 Regional surveillance of antibacterial resistance; 1.2.1 WHO African Region; 1.2.2 WHO Region of the Americas; 1.2.3 WHO Eastern Mediterranean Region; 1.2.4 WHO European Region; 1.2.5 WHO South-East Asia Region; 1.2.6 WHO Western Pacific Region; 1.3 References; SECTION 02 Resistance to antibacterial drugs in selected bacteria of international concern; 2.1 Availability of national resistance data; 2.1.1 Key messages
2.2 Resistance data on specific pathogens2.2.1 Escherichia coli - resistance to third-generation cephalosporins and to fluoroquinolones; 2.2.2 Klebsiella pneumoniae - resistance to third-generation cephalosporins and to carbapenems; 2.2.3 Staphylococcus aureus - resistance to methicillin; 2.2.4 Streptococcus pneumoniae - resistance (non-susceptibility) to penicillin; 2.2.5 Nontyphoidal Salmonella - resistance to fluoroquinolones; 2.2.6 Shigella species - resistance to fluoroquinolones; 2.2.7 Neisseria gonorrhoeae - decreased susceptibility to third-generation cephalosporins; 2.3 References SECTION 03 The health and economic burden due to antibacterial resistance3.1 Methods; 3.2 Findings; 3.2.1 Health burden; 3.2.2 Economic burden; 3.3 Knowledge gaps; 3.4 Key messages; 3.5 References; SECTION 04 Surveillance of antimicrobial drug resistance in disease-specific programmes; 4.1 Tuberculosis; 4.1.1 Evolution of drug resistance in tuberculosis; 4.1.2 Surveillance of drug-resistant tuberculosis; 4.1.3 Global public health response to drug-resistant tuberculosis; 4.1.4 Notification of MDR-TB cases and enrolment on treatment 4.1.5 Public health implications: treatment outcomes for multidrug-resistant and extensively drug-resistant tuberculosis4.1.6 Key messages; 4.2 Malaria; 4.2.1 Evolution of antimalarial drug resistance; 4.2.2 Surveillance of antimalarial therapeutic efficacy and resistance; 4.2.3 Global public health implications of antimalarial drug resistance; 4.2.4 Key messages; 4.3 HIV; 4.3.1 Surveillance of anti-HIV drug resistance; 4.3.2 Global public health implications of anti-HIV drug resistance; 4.3.3 Key messages; 4.4 Influenza; 4.4.1 Evolution of resistance in influenza viruses 4.4.2 Anti-influenza drug resistance4.4.3 Surveillance of anti-influenza drug resistance; 4.4.4 Public health implications of anti-influenza drug resistance; 4.4.5 Key messages; 4.5 References; SECTION 05 Surveillance of antimicrobial resistance in other areas; 5.1 Antibacterial resistance in food-producing animals and the food chain; 5.1.1 Ongoing surveillance of antimicrobial resistance in food-producing animals and food; 5.1.2 Integrated surveillance of antimicrobial resistance in foodborne bacteria; 5.1.3 Antimicrobials of particular importance in human and veterinary medicine 5.1.4 Implications for human health from zoonotic transmission of resistant bacteria and genetic material |
| Record Nr. | UNINA-9910825162403321 |
|
Organization World Health
|
||
| Geneva, : World Health Organization, 2014 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
| Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910139613803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials
| Antiviral Drugs [[electronic resource] ] : From Basic Discovery Through Clinical Trials |
| Autore | Kazmierski Wieslaw M |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (470 p.) |
| Disciplina | 615/.7924 |
| Soggetto topico |
Antiviral Agents -- therapeutic use
Antiviral agents Clinical Trials as Topic Drug Discovery Drug Evaluation Epidemiologic Studies Chemistry, Pharmaceutical Evaluation Studies as Topic Investigative Techniques Anti-Infective Agents Epidemiologic Methods Pharmacology Therapeutic Uses Health Care Evaluation Mechanisms Chemistry Biological Science Disciplines Natural Science Disciplines Quality of Health Care Public Health Pharmacologic Actions Environment and Public Health Health Care Quality, Access, and Evaluation Chemical Actions and Uses Health Care Antiviral Agents Health & Biological Sciences Pharmacy, Therapeutics, & Pharmacology |
| ISBN |
1-283-20363-4
9786613203632 0-470-92935-9 0-470-92934-0 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
ANTIVIRAL DRUGS; CONTENTS; CONTRIBUTORS; PREFACE; PART I HUMAN IMMUNODEFICIENCY VIRUS; 1 Discovery and Development of Atazanavir; 2 Discovery and Development of PL-100, A Novel HIV-1 Protease Inhibitor; 3 Darunavir (Prezista, TMC114): From Bench to Clinic, Improving Treatment Options for HIV-Infected Patients; 4 Discovery and Development of Tipranavir; 5 TMC278 (Rilpivirine): A Next-Generation NNRTI in Phase III Clinical Development for Treatment-Naive Patients; 6 Etravirine: From TMC125 to Intelence: A Treatment Paradigm Shift for HIV-Infected Patients
7 Discovery and Development of Tenofovir Disoproxil Fumarate8 Discovery and Development of Apricitabine; 9 Discovery and Development of Maraviroc and PF-232798: CCR5 Antagonists for the Treatment of HIV-1 Infection; 10 Discovery of the CCR5 Antagonist Vicriviroc (Sch 417690/Sch-D) for the Treatment of HIV-1 Infection; 11 Discovery and Development of HIV-1 Entry Inhibitors That Target gp120; 12 Discovery of MK-0536: A Potential Second-Generation HIV-1 Integrase Strand Transfer Inhibitor with a High Genetic Barrier to Mutation; 13 Discovery and Development of HIV Integrase Inhibitor Raltegravir 14 Elvitegravir: A Novel Monoketo Acid HIV-1 Integrase Strand Transfer InhibitorPART II HEPATITIS C VIRUS; 15 Discovery and Development of Telaprevir; 16 Discovery and Development of BILN 2061 and Follow-up BI 201335; 17 Intervention of Hepatitis C Replication Through NS3-4A, the Protease Inhibitor Boceprevir; 18 Discovery and Development of the HCV NS3/4A Protease Inhibitor Danoprevir (ITMN-191/RG7227); 19 Discovery and Development of the HCV Protease Inhibitor TMC435; 20 Discovery and Clinical Evaluation of the Nucleoside Analog Balapiravir (R1626) for the Treatment of HCV Infection 21 Discovery and Development of PSI-6130/RG712822 Discovery of Cyclophilin Inhibitor NIM811 as a Novel Therapeutic Agent for HCV; 23 HCV Viral Entry Inhibitors; PART III RESPIRATORY SYNCYTIAL VIRUS INHIBITORS; 24 Discovery of the RSV Inhibitor TMC353121; 25 Discovery and Development of Orally Active RSV Fusion Inhibitors; 26 Discovery and Development of RSV604; PART IV INFLUENZA, HEPATITIS B, AND CYTOMEGALOVIRUS INHIBITORS; 27 Discovery and Development of Influenza Virus Sialidase Inhibitor Relenza; 28 Discovery and Development of Entecavir 29 Benzimidazole Ribonucleosides: Novel Drug Candidates for the Prevention and Treatment of Cytomegalovirus DiseasesINDEX; Color Plate |
| Record Nr. | UNINA-9910808713803321 |
|
Kazmierski Wieslaw M
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Antropologia dell'olfatto / / Alessandro Gusman
| Antropologia dell'olfatto / / Alessandro Gusman |
| Autore | Gusman Alessandro |
| Pubbl/distr/stampa | Roma [etc.], : GLF editori Laterza, 2004 |
| Descrizione fisica | ix, 183 p. ; ; 21 cm |
| Disciplina |
301
152 306 612 |
| Collana |
Antropologia
Percorsi |
| Soggetto topico |
Sensation
Environment Anthropology Psychophysiology Environment and Public Health Nervous System Physiological Processes Social Sciences Ecological and Environmental Phenomena Biological Phenomena Health Care Nervous System Physiological Phenomena Psychological Phenomena and Processes Anthropology, Education, Sociology and Social Phenomena Psychiatry and Psychology Musculoskeletal and Neural Physiological Phenomena Phenomena and Processes Odors Smell Anthropology, Cultural |
| ISBN | 88-581-1860-X |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | ita |
| Record Nr. | UNINA-9910132989503321 |
|
Gusman Alessandro
|
||
| Roma [etc.], : GLF editori Laterza, 2004 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]]
| Applications of Toxicogenomics in Safety Evaluation and Risk Assessment [[electronic resource]] |
| Autore | Boverhof Darrell R |
| Pubbl/distr/stampa | Hoboken, : Wiley, 2011 |
| Descrizione fisica | 1 online resource (402 p.) |
| Disciplina |
616.042
616/.042 |
| Altri autori (Persone) | GollapudiB. Bhaskar |
| Soggetto topico |
Genetic toxicology
Health risk assessment Risk Assessment Toxicity testing Toxicogenetics Toxicology Pharmacogenetics Risk Risk Management Epidemiologic Measurements Organization and Administration Pharmacology Probability Genetics Public Health Health Occupations Statistics as Topic Biological Science Disciplines Biology Health Services Administration Environment and Public Health Natural Science Disciplines Health Care Health Care Evaluation Mechanisms Epidemiologic Methods Quality of Health Care Investigative Techniques Health Care Quality, Access, and Evaluation Health & Biological Sciences Toxicology & Public Health |
| Soggetto genere / forma | Electronic books. |
| ISBN |
1-283-23966-3
9786613239662 1-118-00104-4 1-118-00103-6 |
| Formato | Materiale a stampa |
| Livello bibliografico | Monografia |
| Lingua di pubblicazione | eng |
| Nota di contenuto |
Contents; Preface; Contributors; 1 Toxicology, ""Omics"" Technologies, and Toxicogenomics: A Primer; 2 Introduction to Human Health Risk Assessment; 3 Practical Considerations for the Application of Toxicogenomics to Risk Assessment: Early Experience, Current Drivers, and a Path Forward; 4 Approaches and Practical Considerations for the Analysis of Toxicogenomics Data; 5 Genomics in Identifying Mutagenic Mode of Action in Carcinogenesis; 6 Application of Genomics for Predicting and Understanding the Mode of Action for Nongenotoxic Carcinogens; 7 Genomics in Characterizing Endocrine Toxicity
8 Studying Organ-Specific Toxicity Using Gene-Expression Profiling9 Toxicogenomic Studies in Human Populations; 10 Toxicogenomics Applied to Ecological Risk Assessment; 11 Analysis of Transcriptomic Dose-Response Data for Toxicology and Risk Assessment; 12 Toxicogenomics as a Tool for Validating Animal to Human Extrapolations in Chemical Risk Assessment: Concepts, Applications, and Challenges; 13 Toxicogenomics and Animal Alternatives; 14 Toxicogenomics and the Regulatory Framework; 15 Standardization of Gene-Expression Information for the Safety Evaluation: Activities in Japan 16 Applying Transcriptional Profiling in Drug Safety Evaluation17 Reframing the Risk Assessment Paradigm: Toward a Systems Biology Approach; Index |
| Record Nr. | UNINA-9910139607903321 |
|
Boverhof Darrell R
|
||
| Hoboken, : Wiley, 2011 | ||
| Materiale a stampa | ||
| Lo trovi qui: Univ. Federico II | ||
| ||
Soggetto topico
-
Environment and Public Health
(238)
- Health Care (232)
- Public Health (227)
- Health & Biological Sciences (143)
- Investigative Techniques (133)